Advertisement

Viral Elimination Reduces Incidence of Malignant Lymphoma in Patients with Hepatitis C

      Abstract

      Purpose

      A high prevalence of malignant lymphoma among patients with hepatitis C virus (HCV) infection has been reported. The aim of this retrospective study was to determine the incidence of malignant lymphoma and the relationship between malignant lymphoma and viral elimination in patients with HCV.

      Method

      We studied 501 consecutive HCV-infected patients who had never received interferon therapy and 2708 consecutive HCV-infected patients who received interferon therapy.

      Results

      In the non-interferon group, the cumulative rates of malignant lymphoma development were 0.6% at the 5th year, 2.3% at the 10th year, and 2.6% at the 15th year. The cumulative rates of malignant lymphoma development in interferon-treated patients with sustained virologic response were 0% at the 5th year, 0% at the 10th year, and 0% at the 15th year. The cumulative rates of malignant lymphoma development with persistent infection were 0.4% at the 5th year, 1.5% at the 10th year, and 2.6% at the 15th year. The malignant lymphoma development rate was higher in patients with persistent infection than in patients with sustained virologic response (P=.0159). The hazard ratio of lymphomagenesis in 1048 patients with sustained virologic response was significantly lower than in patients with persistent infection (hazard ratio: 0.13; P=.049).

      Conclusion

      Our retrospective study is the first to determine the annual incidence of malignant lymphoma among patients with HCV at 0.23%. Our results indicate that sustained virologic response induced by interferon therapy protects against the development of malignant lymphoma in patients with chronic HCV.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bruix J.
        • Barrera J.M.
        • Calvet X.
        • et al.
        Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.
        Lancet. 1989; ii: 1004-1006
        • Colombo M.
        • Kuo G.
        • Choo Q.L.
        • et al.
        Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma.
        Lancet. 1989; ii: 1006-1008
        • Hasan F.
        • Jeffers L.J.
        • De Medina M.
        • et al.
        Hepatitis C-associated hepatocellular carcinoma.
        Hepatology. 1990; 12: 589-591
        • Kew M.C.
        • Houghton M.
        • Choo Q.L.
        • et al.
        Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma.
        Lancet. 1990; 335: 873-874
        • Ohkoshi S.
        • Kojima H.
        • Tawaraya H.
        • et al.
        Prevalence of antibody against non-A, non-B hepatitis virus in Japanese patients with hepatocellular carcinoma.
        Jpn J Cancer Res. 1990; 81: 550-553
        • Saito I.
        • Miyamura T.
        • Ohbayashi A.
        • et al.
        Hepatitis C virus infection is associated with the development of hepatocellular carcinoma.
        Proc Natl Acad Sci U S A. 1990; 87: 6547-6549
        • Kiyosawa K.
        • Furuta S.
        Review of hepatitis C in Japan.
        J Gastroenterol Hepatol. 1991; 6: 383-391
        • Alter M.J.
        • Margolis H.S.
        • Krawczynski K.
        • et al.
        The natural history of community acquired hepatitis C in the United States.
        N Engl J Med. 1992; 327: 1899-1905
        • Tsukuma H.
        • Hiyama T.
        • Tanaka S.
        • et al.
        Risk factors for hepatocellular carcinoma among patients with chronic liver disease.
        N Engl J Med. 1993; 328: 1797-1801
        • Ikeda K.
        • Saitoh S.
        • Koida I.
        • et al.
        A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.
        Hepatology. 1993; 18: 47-53
        • Ferri C.
        • Monti M.
        • La Civita L.
        • et al.
        Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia.
        Blood. 1993; 82: 3701-3704
        • Agnello V.
        • Chung R.T.
        • Kaplan L.M.
        A role for hepatitis C virus infection in type II cryoglobulinemia.
        N Engl J Med. 1992; 327: 1490-1495
        • Franzin F.
        • Efremov D.G.
        • Pozzato G.
        • et al.
        Clonal B-cell expansions in peripheral blood of HCV-infected patients.
        Br J Haematol. 1995; 90: 548-552
        • Gisbert J.P.
        • Garcia-Buey L.
        • Pajares J.M.
        • et al.
        Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis.
        Gastroenterology. 2003; 125: 1723-1732
        • Matsuo K.
        • Kusano A.
        • Sugumar A.
        • et al.
        Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies.
        Cancer Sci. 2004; 95: 745-752
        • Zuckerman E.
        • Zuckerman T.
        • Sahar D.
        • et al.
        The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection.
        Blood. 2001; 97: 1555-1559
        • Desmet V.J.
        • Gerber M.
        • Hoofnagle J.H.
        • et al.
        Classification of chronic hepatitis: diagnosis, grading and staging.
        Hepatology. 1994; 19: 1513-1520
        • Harris N.L.
        • Jaffe E.S.
        • Stein H.
        • et al.
        A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
        Blood. 1994; 84: 1361-1392
        • Harris N.L.
        Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group).
        Ann Oncol. 1997; 8: 11-16
        • Turner N.C.
        • Dusheiko G.
        • Jones A.
        Hepatitis C and B-cell lymphoma.
        Ann Oncol. 2003; 14: 1341-1345
        • Vallisa D.
        • Bernuzzi P.
        • Arcaini L.
        • et al.
        Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian.
        J Clin Oncol. 2005; 23: 468-473
        • Lymphoma Study Group of Japanese Pathologists
        The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities.
        Pathol Int. 2000; 50: 696-702

      Linked Article

      • Erratum
        The American Journal of MedicineVol. 121Issue 12
        • Preview
          Kawamura Y, Ikeda K, Arase Y, et al. Viral Elimination Reduces Incidence of Malignant Lymphoma in Patients with Hepatitis C. Am J Med. 2007;120:12:1034-1041.
        • Full-Text
        • PDF